One major difference between the models of glucagon signalling deficiency and people with MASLD is that the former have improved glucose tolerance compared to controls, whereas people with MASLD have a high prevalence of pre-diabetes and type 2 diabetes (Cao et al. 2024). This evidence concerns the gene GCG and hyperinsulinemic hypoglycemia, familial, 4.